| Characteristics | Included Patients, n = 234 | Excluded Patients, n = 66 |
|---|---|---|
| Males | 169 (73.5) | 49 (75.4) |
| Age, yrs, mean (SD) | 45.5 (11.8) | 45.3 (11.9) |
| Time since AS onset, yrs, mean (SD) | 21.7 (11.7) | 20.9 (12.1) |
| White | 206 (97.6) | 56 (91.8) |
| Education above end of high school | 141 (61.3) | 32 (50.8) |
| Paid employment | 176 (75.5) | 45 (68.2) |
| History of extraarticular symptoms | ||
| Uveitis, psoriasis, and/or IBD | 116 (51.8) | 30 (53.6) |
| Psoriasis | 37 (17.5) | 9 (17.6) |
| Uveitis | 81 (37.2) | 19 (36.5) |
| IBD | 42 (19) | 12 (21.4) |
| Family history of AS | 69 (29.5) | 15 (25.9) |
| Medication, previous month | ||
| NSAID | 220 (94.0) | 62 (93.9) |
| csDMARD | 55 (23.5) | 11 (16.7) |
| Anti-TNF | 18 (7.7) | 2 (3.0) |
| BASDAI, mean (SD) | 4.4 (2.3) | 4.5 (2.5) |
| BASFI, mean (SD) | 3.4 (2.6) | 4.3 (2.8) |
| ASQoL, mean (SD) | 6.7 (5.5) | 7.9 (5.4) |
| PASS, acceptable state | 135 (59.2) | 37 (58.7) |
AS: ankylosing spondylitis; IBD: inflammatory bowel disease; NSAID: nonsteroidal antiinflammatory drug; csDMARD: conventional synthetic disease-modifying antirheumatic drug; anti-TNF: antitumor necrosis factor; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; ASQoL: AS Quality of Life; PASS: Patient-Acceptable Symptom State.